ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Jun 09, 2021 13:44 JST
Source:
Eisai
Eisai Receives Special Prize at Platinum Career Award 2021
TOKYO, Jun 09, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has received a special prize at the Platinum Career Award 2021. The awards ceremony was held via online at the symposium on June 8, 2021.
The Platinum Career Award was established in 2019 with the aim of commending companies that aspire to provide opportunities for employees to develop their career and play an active role, in order to realize career paths that Japanese employees are aiming for in the era of the 100 years' life. (This event was held with sponsorship and planning by Mitsubishi Research Institute, Inc., planning by Mitsubishi UFJ Trust and Banking Corporation, support by the Ministry of Health, Labour and Welfare, Japan, and Tokyo Stock Exchange, Inc., and cooperation from TOYO KEIZAI INC.). Eisai received a special prize dedicated to companies that are implementing "new working styles initiated to adjust with the era of Corona (COVID-19 Pandemic)".
Eisai defines our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," in the articles of incorporation, which we call our human health care (hhc) philosophy.
Eisai will enhance the development of self-reliant talents, so that each and every employee who sympathize with its corporate philosophy can adapt themselves to any changes and contribute to the creation of new social value through working independently with high motivation. By promoting work and learning style reforms to achieve this goal, Eisai attempts to transition from a company-led career development style to a proactive career development style based on the diversity of values of individual employees and their willingness to take on challenges. In addition, Eisai will work on expanding the range of individual discretion in choosing work locations and working hours, as well as implementing new measures for utilizing IT tools in terms of both hardware and software, such as efficiently providing training opportunities for all employees to independently learn new skills and acquire new working experiences, adopting a special paid leave system that can be used for self-development and social contribution activities, and promoting online dialogue between members inside and outside the organization.
Eisai will make continuous efforts based on the hhc philosophy to further contribute to increasing the benefits of patients and their families around the world.
Source: Eisai
Sectors: BioTech
Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
Eisai Satisfies All-Case Surveillance Requirement for Anticancer Agent Remitoro
May 16, 2025 17:21 JST
Premiere of New bZ Woodland BEV Focused on Driving Performance and Spaciousness in North America
May 16, 2025 16:35 JST
Mitsubishi Heavy Industries Activates New Driving Force for Data Center Business in the United States
May 16, 2025 15:43 JST
MHI Thermal Systems Receives JSRAE Technology Award
May 15, 2025 20:08 JST
Honda and Quemix Co-develop a New, World's First Quantum State Readout Technology
May 15, 2025 13:37 JST
Mitsubishi Electric Building Solutions Launches a New Projection-type Hall Lantern for Overseas Markets
May 15, 2025 11:00 JST
MHI Starts Operation of New CO2 Capture Pilot Plant at KEPCO's Himeji No.2 Power Station
May 14, 2025 16:50 JST
Making Anime More Interesting and Taking it into the Future, Launch of Three New Projects
May 14, 2025 11:00 JST
Adyen and JCB launch Card-on-File Tokenization to Enhance Payment Security
May 13, 2025 11:00 JST
TOYOTA GAZOO Racing fights back for double points finish
May 12, 2025 15:45 JST
JCB and Arab Bank launch JCB merchant acquiring operations across Jordan
May 12, 2025 11:00 JST
Mitsubishi Heavy Industries Achieves Highest-Ever Order Intake, Revenue, Net Income, and Free Cash Flow in FY2024, Increases Dividends, and Releases FY2025 Guidance
May 09, 2025 18:57 JST
Valuufy Selected by Global Tech Leader for Environmental Impact Assessment
May 09, 2025 18:00 JST
Mazda Adopts North American Charging Standard for BEVs launched in Japan
May 09, 2025 16:03 JST
Mitsubishi Motors to Launch an All-New BEV Based on Nissan's Next-Generation LEAF in North America in the Second Half of 2026
May 08, 2025 11:25 JST
Mitsubishi Motors and Foxtron Sign MOU for OEM Supply of EV
May 08, 2025 11:08 JST
Everest Medicines Announces NMPA Full Approval of NEFECON, Broadening Treatment Access for IgA Nephropathy Patients in China
May 07, 2025 19:06 JST
Anime Tokyo Station: Mobile Suit Gundam GQuuuuuuX -Beginning- Special Exhibition
May 03, 2025 03:00 JST
TOYOTA GAZOO Racing Set for Spa spectacle
May 02, 2025 19:29 JST
FWD Group reports exceptionally strong first quarter new business update
May 02, 2025 17:00 JST
More Latest Release >>
Related Release
Eisai Satisfies All-Case Surveillance Requirement for Anticancer Agent Remitoro
5/16/2025 5:21:00 PM JST
Eisai Representative Corporate Officer and CEO Haruo Naito Awarded the Order of the Rising Sun, Gold and Silver Star
4/30/2025 2:17:00 PM JST
Leqembi (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union
4/18/2025 4:52:00 PM JST
Eisai to Divest Rights for Pariet in China to Peak Pharma
4/1/2025 1:15:00 PM JST
World's First Early Alzheimer's Disease Treatment Developed in Japan LEQEMBI Receives Prime Minister's Award at the 12th Technology Management and Innovation Awards
3/25/2025 5:28:00 PM JST
Eisai Selected as a Nadeshiko Brand 2025 as a Listed Company Excelling in Promotion of Women in the Workplace
3/25/2025 12:21:00 PM JST
Eisai Recognized as "2025 Kenko Investment for Health" for the First Time and Certified as "Outstanding Organization Of Kenko Investment for Health Program (White 500)" for the Sixth Time
3/10/2025 8:24:00 PM JST
Eisai: Update on the Co-Promotion of the Oral Antifungal Agent Nailin Capsules 100mg in Japan
3/5/2025 9:09:00 AM JST
Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer's Disease in Australia
3/4/2025 5:22:00 PM JST
"Fatigue Recovery While You Sleep!" Eisai to Launch Designated Quasi-Drug Drink "Chocola BB Nightwell"
3/3/2025 3:41:00 PM JST
More Press release >>